216 related articles for article (PubMed ID: 21210113)
1. Value of the radiolabelled GLP-1 receptor antagonist exendin(9-39) for targeting of GLP-1 receptor-expressing pancreatic tissues in mice and humans.
Waser B; Reubi JC
Eur J Nucl Med Mol Imaging; 2011 Jun; 38(6):1054-8. PubMed ID: 21210113
[TBL] [Abstract][Full Text] [Related]
2. Radiolabelled GLP-1 receptor antagonist binds to GLP-1 receptor-expressing human tissues.
Waser B; Reubi JC
Eur J Nucl Med Mol Imaging; 2014 Jun; 41(6):1166-71. PubMed ID: 24519555
[TBL] [Abstract][Full Text] [Related]
3. [Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting.
Wild D; Béhé M; Wicki A; Storch D; Waser B; Gotthardt M; Keil B; Christofori G; Reubi JC; Mäcke HR
J Nucl Med; 2006 Dec; 47(12):2025-33. PubMed ID: 17138746
[TBL] [Abstract][Full Text] [Related]
4. Glucagon-like peptide-1 improves insulin and proinsulin binding on RINm5F cells and human monocytes.
Ebinger M; Jehle DR; Fussgaenger RD; Fehmann HC; Jehle PM
Am J Physiol Endocrinol Metab; 2000 Jul; 279(1):E88-94. PubMed ID: 10893327
[TBL] [Abstract][Full Text] [Related]
5. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells.
Göke R; Fehmann HC; Linn T; Schmidt H; Krause M; Eng J; Göke B
J Biol Chem; 1993 Sep; 268(26):19650-5. PubMed ID: 8396143
[TBL] [Abstract][Full Text] [Related]
6. Use of the incretin hormone glucagon-like peptide-1 (GLP-1) for the detection of insulinomas: initial experimental results.
Gotthardt M; Fischer M; Naeher I; Holz JB; Jungclas H; Fritsch HW; Béhé M; Göke B; Joseph K; Behr TM
Eur J Nucl Med Mol Imaging; 2002 May; 29(5):597-606. PubMed ID: 11976797
[TBL] [Abstract][Full Text] [Related]
7. Glucagon-like peptide-1 (GLP-1) receptors are not overexpressed in pancreatic islets from patients with severe hyperinsulinaemic hypoglycaemia following gastric bypass.
Reubi JC; Perren A; Rehmann R; Waser B; Christ E; Callery M; Goldfine AB; Patti ME
Diabetologia; 2010 Dec; 53(12):2641-5. PubMed ID: 20835917
[TBL] [Abstract][Full Text] [Related]
8. Insulinoma imaging with glucagon-like peptide-1 receptor targeting probe (18)F-FBEM-Cys (39)-exendin-4.
Xu Y; Pan D; Xu Q; Zhu C; Wang L; Chen F; Yang R; Luo S; Yang M
J Cancer Res Clin Oncol; 2014 Sep; 140(9):1479-88. PubMed ID: 24838847
[TBL] [Abstract][Full Text] [Related]
9. Approaches to Improve the Pharmacokinetics of Radiolabeled Glucagon-Like Peptide-1 Receptor Ligands Using Antagonistic Tracers.
Rylova SN; Waser B; Del Pozzo L; Tönnesmann R; Mansi R; Meyer PT; Reubi JC; Maecke HR
J Nucl Med; 2016 Aug; 57(8):1282-8. PubMed ID: 27127218
[TBL] [Abstract][Full Text] [Related]
10. Allosteric modulation of the activity of the glucagon-like peptide-1 (GLP-1) metabolite GLP-1 9-36 amide at the GLP-1 receptor.
Li N; Lu J; Willars GB
PLoS One; 2012; 7(10):e47936. PubMed ID: 23094100
[TBL] [Abstract][Full Text] [Related]
11. The isolated N-terminal domain of the glucagon-like peptide-1 (GLP-1) receptor binds exendin peptides with much higher affinity than GLP-1.
López de Maturana R; Willshaw A; Kuntzsch A; Rudolph R; Donnelly D
J Biol Chem; 2003 Mar; 278(12):10195-200. PubMed ID: 12524435
[TBL] [Abstract][Full Text] [Related]
12. Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor.
Ban K; Kim KH; Cho CK; Sauvé M; Diamandis EP; Backx PH; Drucker DJ; Husain M
Endocrinology; 2010 Apr; 151(4):1520-31. PubMed ID: 20172966
[TBL] [Abstract][Full Text] [Related]
13. Detection of the human glucagon-like peptide 1(7-36) amide receptor on insulinoma-derived cell membranes.
Lankat-Buttgereit B; Göke R; Stöckmann F; Jiang J; Fehmann HC; Göke B
Digestion; 1994; 55(1):29-33. PubMed ID: 8112494
[TBL] [Abstract][Full Text] [Related]
14. Agonist-induced internalization and recycling of the glucagon-like peptide-1 receptor in transfected fibroblasts and in insulinomas.
Widmann C; Dolci W; Thorens B
Biochem J; 1995 Aug; 310 ( Pt 1)(Pt 1):203-14. PubMed ID: 7646446
[TBL] [Abstract][Full Text] [Related]
15. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide.
Kolligs F; Fehmann HC; Göke R; Göke B
Diabetes; 1995 Jan; 44(1):16-9. PubMed ID: 7813808
[TBL] [Abstract][Full Text] [Related]
16. Exendin-4 Derivatives with an Albumin-Binding Moiety Show Decreased Renal Retention and Improved GLP-1 Receptor Targeting.
Kaeppeli SAM; Jodal A; Gotthardt M; Schibli R; Béhé M
Mol Pharm; 2019 Sep; 16(9):3760-3769. PubMed ID: 31393738
[TBL] [Abstract][Full Text] [Related]
17. Glucagonlike peptide-1 receptor: an example of translational research in insulinomas: a review.
Christ E; Wild D; Reubi JC
Endocrinol Metab Clin North Am; 2010 Dec; 39(4):791-800. PubMed ID: 21095545
[TBL] [Abstract][Full Text] [Related]
18. Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas.
Wild D; Christ E; Caplin ME; Kurzawinski TR; Forrer F; Brändle M; Seufert J; Weber WA; Bomanji J; Perren A; Ell PJ; Reubi JC
J Nucl Med; 2011 Jul; 52(7):1073-8. PubMed ID: 21680696
[TBL] [Abstract][Full Text] [Related]
19. Glucagon-like peptide-1 receptor imaging for localization of insulinomas.
Christ E; Wild D; Forrer F; Brändle M; Sahli R; Clerici T; Gloor B; Martius F; Maecke H; Reubi JC
J Clin Endocrinol Metab; 2009 Nov; 94(11):4398-405. PubMed ID: 19820010
[TBL] [Abstract][Full Text] [Related]
20. Structure-activity relationships of glucagon-like peptide-1(7-36)amide: insulinotropic activities in perfused rat pancreases, and receptor binding and cyclic AMP production in RINm5F cells.
Watanabe Y; Kawai K; Ohashi S; Yokota C; Suzuki S; Yamashita K
J Endocrinol; 1994 Jan; 140(1):45-52. PubMed ID: 8138751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]